Affiliation:
1. College of Pharmacy, The University of Iowa,1 and
2. Department of Pathology, The University of Iowa Hospitals and Clinics,2Iowa City, Iowa 52242
Abstract
ABSTRACT
We have previously reported poor correlation between the in vitro fungicidal activity of LY303366 and MIC results in RPMI medium based upon the manufacturer’s suggested susceptibility endpoint, lack of visual growth. Additionally, we have noted a significant trailing effect with LY303366 when MICs are determined in RPMI medium. These observations have led us to evaluate an alternative susceptibility endpoint for LY303366, an 80% reduction in growth compared with control (similar to that utilized for azoles). Two isolates each of
Candida albicans
,
Candida glabrata
, and
Candida tropicalis
were selected for testing. MICs were determined for LY303366 in RPMI 1640 medium buffered with morpholinepropanesulfonic acid. MICs were determined with suggested (MIC
100
) and experimental (MIC
80
) endpoints. The minimal fungicidal concentration (MFC) of LY303366 for each isolate was also determined. Time-kill curves were determined in RPMI medium with each isolate at concentrations of LY303366 ranging from 0.125 to 16× MIC
80
to assess the correlation between MIC
80
and fungicidal activity. Lastly, fungi exposed to LY303366 were examined via scanning electron microscope (SEM) for evidence of drug-induced ultrastructure change. MIC
80
s for test isolates ranged from 0.015 to 0.12 μg/ml and were consistently three to five wells less than MIC
100
s. Good correlation was observed between fungicidal activity, as assessed by kill curves, and the MIC
80
. SEM data revealed significant ultrastructure changes induced by LY303366 even at sub-MIC
80
s. Based on our results demonstrating better correlation between MIC
80
and fungicidal activity, i.e., time-kill curves and MFCs, we suggest that 80% reduction in visible growth be utilized as the endpoint for susceptibility determinations with LY303366 in RPMI medium.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference11 articles.
1. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp.;Ernst M. E.;Diagn. Microbiol. Infect. Dis.,1996
2. Klepser
M. E.
Ernst
E. J.
Ernst
M. E.
Messer
S. A.
Pfaller
M. A.
Evaluation of the endpoint for antifungal susceptibility determinations with LY303366 abstr. F-71
Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy.
1997
158
American Society for Microbiology
Washington D.C
3. Growth medium effect on the antifungal activity of LY 303366.;Klepser M. E.;Diagn. Microbiol. Infect. Dis.,1997
4. Klepser
M. E.
Ernst
E. J.
Ernst
M. E.
Lewis
R. E.
Pfaller
M. A.
Antifungal time-kill curves influence of test conditions on results abstr. D-144
Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy.
1997
109
American Society for Microbiology
Washington D.C
5. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献